A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Mayo Clinic Hospital, Scottsdale, Arizona +144 locations
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled, treat-through study will evaluate the efficacy and safety of Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
07/28/2025
Locations: Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, Dothan, Alabama +278 locations
Conditions: Moderately to Severely Active Ulcerative Colitis
Register for Updates
Imaging of Vitreous Opacities in a Canadian Population
NCT06204848
Recruiting
The goal of this clinical trial is to capture imaging data of eye floaters in the population to build an imaging database to learn more about them in. Participants will imaged with an investigational ophthalmic imaging device to capture images of their floaters.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Alberta Retina Consultants, Edmonton, Alberta
Conditions: Floaters, Vitreous Opacities
Register for Updates
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243
Recruiting
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE). The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs). The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data o... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: Allervie Clinical Research, Birmingham, Alabama +160 locations
Conditions: Chronic Inducible Urticaria
Register for Updates
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Recruiting
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/28/2025
Locations: University of Arizona, Tucson, Arizona +126 locations
Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Register for Updates
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
NCT05126277
Recruiting
This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
07/28/2025
Locations: University Of Alabama, Birmingham, Alabama +184 locations
Conditions: Lupus Nephritis
Register for Updates
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268
Recruiting
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Southern California Clinical Research, Santa Ana, California +52 locations
Conditions: Obesity
Register for Updates
Canadian Medical Assessment of JINARC™ Outcomes Registry
NCT02925221
Recruiting
This study is part of the Health Canada approval requirement for JINARC™ (tolvaptan) and is an observational, non-interventional study (NIS) describing the impact of tolvaptan on ADPKD-related burden of illness as measured with a set of Patient Reported Outcome (PRO) Questionnaires. The study is also describing the time to renal replacement therapy (RRT), such as dialysis and transplantation, and the long-term mortality rate and causes (i.e. renal and hepatic), in ADPKD patients treated with JIN... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Not set, Edmonton, Alberta +5 locations
Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Register for Updates
1% Lidocaine Paracervical Block for Endometrial Biopsy
NCT06546254
Recruiting
The objective of this study is to to determine whether 1% lidocaine paracervical block reduces pain during endometrial biopsy in comparison to no intervention. The proposed study is a double-blind randomized controlled trial (RCT). Each participant will be randomly assigned to one of two arms: 1. intervention (paracervical block - 10 mL 1% lidocaine with epinephrine) 2. control (gently tapping the cervicovaginal junction with a capped needle) The primary outcome will be a global pain score,... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: OPG, Toronto, Ontario
Conditions: Endometrial Biopsy
Register for Updates
Anticoagulation After GI Bleeding Pilot Study and Registry
NCT05290857
Recruiting
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related gastrointestinal (GI) bleeding among patients at moderate to high risk of re-bleeding and thrombosis. A parallel registry will assess whether eligible patients who are not enrolled in the PANTHER-GI Pilot Study are systematically different than enrolled patients and to explo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Alberta Health Services - Peter Lougheed Center Endoscopy Unit, Calgary, Alberta +1 locations
Conditions: GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Register for Updates
Cannabidiol After Multi-Trauma for Pain and Opioid Therapy
NCT06448923
Recruiting
The aim of this project is to investigate the therapeutic potential and safety of acute Cannabidiol (CBD) treatment on longitudinal pain symptoms, and to assess potential interactions with pain mediators including opioids and sex on CBD treatment response. To this end, this research protocol proposes a comprehensive translational approach including a placebo-controlled randomized clinical trial comparing two daily doses of CBD treatment administered for one month on pain relief. This study will... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/28/2025
Locations: Hôpital Sacré-Coeur de Montréal, Montréal, Quebec
Conditions: Fracture
Register for Updates
NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment
NCT06537154
Recruiting
Invasive bladder cancer is managed with neoadjuvant therapy followed by bladder removal (cystectomy). Research shows that approximately 40% of patient will have no remaining cancer left in their bladder after completion of the initial systemic treatment, and perhaps could have avoided the surgery. However, currently physicians lack the ability to identify these patients. The investigators believe that by using advanced imaging (MRI), bladder biopsies and novel biomarkers that detect tumor DNA i... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/28/2025
Locations: Vancouver Prostate Centre, Vancouver, British Columbia
Conditions: Muscle-Invasive Bladder Carcinoma
Register for Updates